Viva's Portfolio Companies Announce Significant Advances in Biopharmaceutical Innovations
AcuraStem and Takeda Collaborate on ALS Treatment
AcuraStem, a biotechnology company focused on neurodegenerative diseases, has entered into a license agreement with Takeda. This partnership aims to develop and commercialize PIKFYVE targeted therapeutics, including AS-202, an innovative antisense oligonucleotide (ASO) for treating Amyotrophic Lateral Sclerosis (ALS). The agreement could see AcuraStem receiving up to $580 million in upfront and milestone payments, plus royalties on net sales of any commercial products resulting from this license.
ABM-1310 Receives FDA Fast Track Designation
ABM Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABM-1310 for the treatment of glioblastoma multiforme (GBM) with a BRAF V600E mutation. This follows the Orphan Drug designation for ABM-1310 for malignant glioma treatment. The first patient has been dosed in a Phase I study of ABM-1310 for relapsed and drug-resistant primary malignant brain tumors at Beijing Tiantan Hospital.
QureBio's Q-1802 Project Gains Recognition
QureBio's bispecific antibody Q-1802 project has been selected for the Shanghai 2023 Sci-Tech SME Innovation Fund. Q-1802 is a First-in-Class CLDN18.2 bispecific antibody that has shown excellent safety and efficacy in clinical trials, with positive Phase I clinical data indicating a strong risk-benefit ratio among similar biomarker-targeting products.
These advancements underscore the commitment of Viva BioInnovator's portfolio companies to addressing unmet medical needs through innovative biopharmaceutical solutions.